Twenty-four hour ambulatory gastric and duodenal pH profiles in cystic fibrosis: effect of duodenal hyperacidity on pancreatic enzyme function and fat absorption.
Overt steatorrhoea remains a problem for some patients with cystic fibrosis (CF) despite supraphysiological dosages of pancreatic enzymes. As pancreatin release and enzyme function is influenced by duodenal pH, we have used 24-h ambulatory pH measurements to assess the extent and duration of postprandial hyperacidity. Readings were obtained from the stomach and proximal duodenum in 16 CF patients (aged 6 months to 12 years) using a dual-channel antimony electrode. The fasting gastric and duodenal pH values were normal in all patients (mean pH values of 1.3, and 6.8, respectively). There was, however, a marked drop in duodenal pH in the first postprandial hour, which became more pronounced with successive meals. The total time that duodenal pH was < 5 varied from 15 to 90% of the recording (mean 57%). Overnight the duodenal pH returned to normal levels. A subgroup of five patients were studied before and after treatment with omeprazole, a potent inhibitor of gastric acid secretion. There were significant improvements in both weight gain and fat absorption. This study supports the hypothesis that the postprandial duodenal pH is excessively acid in patients with CF and may be an important element in the continuing fat malabsorption experienced by some patients. This malabsorption may limit the efficacy of the newer high-lipase pancreatic enzyme supplements and lead to delayed enzyme release, a possible factor in the recent reports of proximal colonic strictures.
Barraclough
M
M
Department of Paediatrics, University of Sheffield, England.
Taylor
C J
CJ
D000042:Absorption; D000143:Acids / Q000737:chemistry; D002648:Child; D002675:Child, Preschool; D002940:Circadian Rhythm; D003550:Cystic Fibrosis / Q000503:physiopathology*; D004041:Dietary Fats / Q000493:pharmacokinetics*; D004386:Duodenum / Q000737:chemistry* / Q000503:physiopathology; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007223:Infant; D008049:Lipase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D008297:Male; D009853:Omeprazole / Q000494:pharmacology / Q000627:therapeutic use; D019518:Postprandial Period; D013270:Stomach / Q000737:chemistry* / Q000503:physiopathology; D013997:Time Factors; D014280:Triglycerides / Q000032:analysis; D015430:Weight Gain / Q000187:drug effects
D000143:Acids; D004041:Dietary Fats; D004791:Enzyme Inhibitors; D014280:Triglycerides; D008049:Lipase; D009853:Omeprazole